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1Early after acute ST-elevation myocardial infarction (STEMI), tissue edema and inflammatory cell recruit-
ment occur as a response to myocyte necrosis and systemic 
inflammation.1 The tissue repair response involves remodeling 
with collagen deposition in both the infarct and remote (nonin-
farcted myocardium) zones.1,2 On the basis of recent develop-
ments with cardiac magnetic resonance (CMR) imaging, it is 
now possible to estimate the percentage extracellular volume 
(ECV) in defined regions of interest.3,4
The pathophysiological and clinical significance of remote 
zone ECV in survivors of acute STEMI is incompletely under-
stood. To date, studies of remote zone ECV have included 
patients with chronic myocardial infarction (MI) as a small 
subgroup (n<50).3,4 Furthermore, these studies are cross-sec-
tional, and the changes that may occur in remote myocardium 
over time have not been investigated.
Our specific aims were to (1) measure ECV repeat-
edly in STEMI survivors in a longitudinal cohort study; (2) 
explore the relationships between remote zone ECV 2 days 
post STEMI and its absolute change at 6 months from base-
line (ΔECV) with clinical characteristics of MI severity; and 
(3) assess whether remote zone ECV or ΔECV are associated 
with surrogate left ventricular (LV) outcomes during long-
term follow-up.
Abstract—The natural history and pathophysiological significance of tissue remodeling in the myocardial remote zone 
after acute ST-elevation myocardial infarction (STEMI) is incompletely understood. Extracellular volume (ECV) in 
myocardial regions of interest can now be measured with cardiac magnetic resonance imaging. Patients who sustained an 
acute STEMI were enrolled in a cohort study (BHF MR-MI [British Heart Foundation Magnetic Resonance Imaging in 
Acute ST-Segment Elevation Myocardial Infarction study]). Cardiac magnetic resonance was performed at 1.5 Tesla at 
2 days and 6 months post STEMI. T1 modified Look-Locker inversion recovery mapping was performed before and 15 
minutes after contrast (0.15 mmol/kg gadoterate meglumine) in 140 patients at 2 days post STEMI (mean age: 59 years, 
76% male) and in 131 patients at 6 months post STEMI. Remote zone ECV was lower than infarct zone ECV (25.6±2.8% 
versus 51.4±8.9%; P<0.001). In multivariable regression, left ventricular ejection fraction was inversely associated with 
remote zone ECV (P<0.001), and diabetes mellitus was positively associated with remote zone ECV (P=0.010). No ST-
segment resolution (P=0.034) and extent of ischemic area at risk (P<0.001) were multivariable associates of the change 
in remote zone ECV at 6 months (ΔECV). ΔECV was a multivariable associate of the change in left ventricular end-
diastolic volume at 6 months (regression coefficient [95% confidence interval]: 1.43 (0.10–2.76); P=0.036). ΔECV is 
implicated in the pathophysiology of left ventricular remodeling post STEMI, but because the effect size is small, ΔECV 
has limited use as a clinical biomarker of remodeling.
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Our objective was to assess the pathophysiological 
significance of remote zone ECV and LV remodeling in 
patients after an acute STEMI. We hypothesized that ECV 
in the remote myocardial regions of patients with STEMI 
would be associated with measures of severity of MI and 
6-month LV volumes. To test this hypothesis, we investi-
gated ECV repeatedly during longitudinal follow-up of 
STEMI survivors and assessed the associations for remote 




We enrolled invasively managed patients with acute STEMI5,6 into 
a CMR cohort study in a regional cardiac center between January 
3, 2012, and November 22, 2012. The study was approved by the 
National Research Ethics Service (Reference 10-S0703-28) and 
was publically registered (NCT020728507). Healthy volunteers also 
underwent CMR. All the participants provided written informed con-
sent. The Methods section in the online-only Data Supplement pro-
vides a detailed description of the protocol and methods.
Statistics
For a sample size of 110 subjects, a minimum clinically significant 
correlation between remote zone ECV at baseline and the within-
subject change in LV end-diastolic volume at 6 months from baseline 
could be detected with 90% power and an α of 0.05.
Continuous variables are described as mean±SD if normally dis-
tributed, and median (Q1–Q3) otherwise. Categorical variables are 
described as n (%). Variables were described overall and by tertiles of 
remote zone ECV. Patient and angiographic characteristics and CMR 
findings were compared across ECV tertiles using 1-way ANOVA, 
Kruskal–Wallis tests, or Fisher tests. Variables were compared be-
tween patients and healthy volunteers using t tests, Mann–Whitney 
tests, or Fisher tests. Associations between continuous variables were 
assessed using Pearson correlation coefficient. ECV was compared 
between segments using t tests. Multivariable linear regression analy-
ses were performed to identify associates of remote zone ECV, ΔECV, 
and LV outcome. Backward selection was performed, and the remain-
ing variables were included in the multivariable models. Linear regres-
sion assumptions were verified using standardized residual plots.
Random effects models were used to compute inter-rater reliability 
measures (interclass correlation coefficient) for the reliability of remote 
zone ECV values measured independently by 2 observers in 20 random-
ly selected patients from the cohort. Root mean square error was cal-
culated. Bland–Altman plots were assessed for interobserver reliability 
and for agreement between synthetic and conventional ECV measures.
Cox proportional hazards regression was used to explore poten-
tial associations between ECV and health outcome. The propor-
tional hazards assumption was verified using log-minus-log plots. 
For these plots, continuous variables were categorized as above and 
below the median.
All P values were 2 sided. A P value >0.05 indicated the absence of 
a statistically significant effect. The natural log was used in transfor-
mations of variables. Analyses were performed using SPSS version 
22 for Windows (SPSS, Inc, Chicago, IL).
Results
One hundred and forty patients with STEMI underwent CMR 
including pre- and postcontrast T1-mapping at 2.3±1.9 days 
post revascularization. One hundred and thirty-two patients 
(94%) had 6-month CMR, of whom 131 (94%) had pre- and 
postcontrast T1-mapping allowing for the measurement of ECV. 
Clinical case examples are shown in Figure 1. One thousand six 
hundred and eighty segments at baseline and 1572 at 6 months 
were included for analysis. The flow diagram for the study is 
shown in Figure S1 in the online-only Data Supplement.
Patient Characteristics
The characteristics of patients with remote zone ECV mea-
surement at baseline (n=140) are described in Table 1. The 
mean±SD age was 59±11 years, and 76% were male.
Myocardial ECV in Patients With STEMI and 
Healthy Volunteers
Fifteen sex-matched healthy volunteers (age: 60±13 years, 
73% male) also underwent CMR assessment of ECV. 
Remote zone ECV was similar in patients with STEMI 
(25.6±2.8%) and healthy volunteers (25.4±3.2%; P=0.797). 
In healthy volunteers, ECV was associated with myocardial 
T2-relaxation time (ms; regression coefficient [95% confi-
dence intervals]: 0.90 [0.38–1.41]; P=0.002). Further analy-
sis of healthy volunteer ECV is included in Results in the 
online-only Data Supplement. The results of interobserver 
agreement of remote zone ECV measurements are shown 
in Figure S2.
Remote Zone ECV and CMR Findings in Patients 
With Acute STEMI
The tertiles of remote zone ECV were ≤24.2% (n=46), >24.2 
to ≤26.4% (n=47), and >26.4% (n=47). The proportion of men 
decreased with increasing tertile of ECV (43 [94%] versus 
35 [75%] versus 29 [62%]; P<0.001), and body mass index 
(BMI, kg/m2) reduced with increasing ECV tertile: (30±4 ver-
sus 29±5 versus 27±4; P=0.018).
Statistically significant CMR findings for patients with 
baseline ECV (n=140) are summarized in Table 2. The full 
list of CMR findings are summarized in Table S1. Infarct 
size was 17±12% of LV mass, and 70 patients (50%) had 
microvascular obstruction. Remote zone ECV was lower 
than infarct zone ECV (25.6±2.8% versus 51.4±8.9%; 
P<0.001). The upper tertile of remote zone ECV had val-
ues that overlapped with ECV values observed in the infarct 
zone (Table 2). Remote zone ECV early post MI was posi-
tively associated with the extent of myocardial edema 
(Table 2).
Multivariable Associations Between Clinical 
Characteristics and Remote Zone ECV
The multivariable associates of remote zone ECV at base-
line are described in Table S2. Male sex (−1.85 [−2.91 to 
−0.79]; P=0001), diabetes mellitus (1.82 [0.43–3.20]; 
P=0.010), BMI (kg/m2) (−0.12 [−0.22 to −0.02]; P=0.018), 
and LV ejection fraction at baseline (%) (−0.08 [−0.13 to 
−0.03]; P=0.002) were multivariable associates of remote 
zone ECV. The extent of myocardial edema (% LV mass) 
was also a multivariable associate of remote zone ECV 
(0.09 [0.05–0.14]; P<0.001).
Remote Zone ECV and CMR Findings at 6 Months
The 6-month CMR findings are described in Table 2 and 
Table S1. For patients with paired observations, remote zone 
ECV at baseline and follow-up were similar (25.5±2.9% ver-
sus 25.7±2.8%; P=0.645). The within-subject ΔECV in the 
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remote zone varied markedly (ΔECV 0.1±2.6%). The cor-
relation between remote zone ECV and ΔECV is shown in 
Figure 2.
At 6 months, LV end-diastolic volume increased on 
average±SD by 2±25 mL (Table 2) and adverse LV remodel-
ing (an increase in LV end-diastolic volume >20%) developed 
in 9 patients (7%).
T1- and T2-Relaxation Times and Remote Zone 
ECV
Remote zone T2 was marginally higher at follow-up (49.9±2.2 
ms versus 50.7±2.4 ms; P=0.005; mean change 0.7±3.0 ms). 
ΔECV in the remote zone was not associated with the change 
in remote zone T2 (0.07 [−0.01 to 0.14]; P=0.068). Remote 
zone T1 did not change over time.
Multivariable Associations Between Clinical 
Characteristics and the Changes in Remote ECV at 
6 Months From Baseline
The multivariable associates of ΔECV in the remote zone 
are shown in Table S3. A 1-U increase in BMI (−0.14 [−0.23 
to −0.04]; P=0.005), no ST-segment resolution (1.20 [0.09–
2.31]; P=0.034), and extent of myocardial edema (0.08 
[0.04–0.11]; P<0.001) were independently associated with 
ΔECV.
Remote Zone ECV and LV Remodeling
ΔECV was a multivariable associate of the change in LV 
end-diastolic volume at 6 months (Table 3); however, this 
was dependent on size of infarction (% LV mass; Table 3). 
Baseline remote zone ECV was not associated with LV ejec-
tion fraction or volumes at follow-up.
Remote Zone ECV and NT-proBNP
N-terminal pro-brain natriuretic peptide (NT-proBNP) results 
were available in 82 subjects. The characteristics of these 
patients were similar to the whole cohort (data not shown).
Remote zone ECV and NT-proBNP were associated at 
baseline (0.11 on a log scale [0.03–0.19]; P=0.007). This 
relationship remained after adjustment for LV function and 
volumes. NT-proBNP at baseline was also associated with 
ΔECV (0.14 [0.05–0.24]; P=0.004) after adjustment for base-
line remote zone ECV and independently of LV function and 
volumes.
Remote Zone ECV and Health Outcomes
All-cause death or heart failure hospitalization occurred in 7 
patients (5%), including 1 death and 6 heart failure episodes. 
Three patients (2%) experienced an event post discharge. In 
a preliminary analysis, remote zone ECV was not associated 
with all-cause death and heart failure hospitalization (n=7).
Figure 1. Two patients with similar presentations of acute ST-elevation myocardial infarction (STEMI). Both patients were treated by 
primary percutaneous coronary intervention and with the same medication. At the end of the procedure, both patients had thrombolysis in 
myocardial infarction coronary flow grade 3 in the culprit artery. A, Increasing remote zone extracellular volume (ECV). Cardiac magnetic 
resonance (CMR) performed 2 days post STEMI revealed a remote zone ECV of 28%. Remote zone ECV increased by 4% by 6 months 
to 32%. Left ventricular (LV) end-diastolic volume increased from 116 to 135 mL as measured by the 2-day and 6-month CMR scans. B, 
Decreasing remote zone ECV: CMR performed 2 days post STEMI revealed a remote zone ECV of 22%. Remote zone ECV decreased by 
2% by 6 months to 20%. LV end-diastolic volume decreased from 128 to 102 mL as measured by the 2-day and 6-month CMR scans. 
MRI indicates magnetic resonance imaging.
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Discussion
The main findings are as follows: (1) remote zone ECV 2 
days post MI is associated with male sex, BMI, and a his-
tory of diabetes mellitus; (2) ΔECV is related to the extent 
of injury as revealed by myocardial edema; (3) ΔECV was 
positively associated with changes in LV end-diastolic vol-
ume; (4) remote zone ECV and ΔECV were associated with 
NT-proBNP at baseline. We conclude that in STEMI survi-
vors, an increase in remote zone ECV over time post STEMI 
is associated with an increase in LV end-diastolic volume, fur-
ther implicating remote zone interstitial fibrosis in the patho-
physiology of adverse LV remodeling.
We recently observed that remote zone tissue charac-
teristics, as revealed by the native myocardial longitudinal 
relaxation time (T1), were multivariable associates of acute 
systemic inflammation and subsequent adverse outcomes 
in the longer term, including LV remodeling and all-cause 
death or heart failure.8 The results from the current study 
extend these findings in several ways. First, ECV early post 
MI is inversely associated with the change in ECV over 
time. Our results indicate that remote zone ECV is likely 
Table 1. Characteristics of 140 Patients With STEMI With a 
CMR Measurement of ECV (%) at Baseline
Characteristics All Patients, n=140
Age, y 59±11
Male sex, n (%) 107 (76)
BMI, kg/m2 29±5
Hypertension, n (%) 46 (33)
Current smoking, n (%) 84 (60)
Hypercholesterolemia, n (%) 41 (29)
Diabetes mellitus, n (%)* 16 (11)
Previous angina, n (%) 22 (16)
Previous myocardial infarction, n (%) 10 (7)
Previous PCI, n (%) 8 (6)
Mineralocorticoid receptor antagonist, n (%) 6 (4)
Presenting characteristics
  Heart rate, bpm 78±17
  Systolic blood pressure, mm Hg 139±25
  Diastolic blood pressure, mm Hg 80±14
  Symptom onset to reperfusion, min 247±227
  Ventricular fibrillation, n (%)† 8 (6)
  Killip class, n (%)
   I 105 (75)
   II 31 (22)
   III/IV 4 (3)
ECG
  ST-segment resolution post PCI, n (%)
   Complete, ≥70% 64 (46)
   Incomplete, 30% to <70% 52 (37)
   None, ≤30% 23 (17)
Coronary angiography
  Reperfusion strategy, n (%)
   Primary PCI 132 (94)
   Rescue PCI (failed thrombolysis) 5 (4)
   Successful thrombolysis 3 (2)
  Number of diseased arteries, n (%)‡
   1 78 (56)
   2 41 (29)
   3 19 (14)
  Culprit artery, n (%)
   Left main 2 (1)
   Left anterior descending 55 (39)
   Left circumflex 26 (19)
   Right coronary 59 (42)
  Culprit artery TIMI flow grade at initial 
angiography, n (%)
   0/1 107 (76)
   2 21 (15)
   3 12 (9)
  Culprit artery TIMI flow grade post PCI, n (%)
   0/1 3 (2)
   2 5 (4)
   3 132 (94)
Blood results on admission
  Troponin I, ng/L
   Median (Q1–Q3) 2718 (1248–6377)
   Range 56–28 406
  C-reactive protein, mg/L
   Median (Q1–Q3) 3.0 (2.0–6.0)
   Range 1.0–125.0
  Leucocytes, ×109 L 12.4±3.5
  Neutrophils, ×109 L 9.5±3.3
  Monocytes, ×109 L 0.8±0.3
Data are given as n (%), mean±SD, or median (Q1–Q3) as appropriate. 
Killip classification of heart failure post MI: class I, no heart failure; class 
II, pulmonary rales or crepitations, third heart sound, and elevated jugular 
venous pressure; class III, acute pulmonary edema; class IV, cardiogenic 
shock. BMI indicates body mass index; CMR, cardiac magnetic resonance; 
ECV, extracellular volume; MI, myocardial infarction; PCI, percutaneous 
coronary intervention; STEMI, ST-elevation myocardial infarction; and TIMI, 
thrombolysis in myocardial infarction.
*History of diet-controlled or treated diabetes.
†Successfully electrically cardioverted ventricular fibrillation at presentation 
or during PCI.
‡Number of stenoses ≤50% of the reference vessel diameter by visual 
assessment and if there was left main stem involvement.
Table 1. Continued
Characteristics All Patients, n=140
(Continued )
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to remain persistently elevated in patients with a large MI, 
implying replacement fibrosis and LV remodeling. The 
absence of an association between remote zone ΔECV and 
changes in remote zone T2 (ms) over time implies that the 
persistent elevation in ECV is not explained by edema, indi-
cating that extracellular matrix remodeling and fibrosis is a 
plausible alternative explanation. Second, the changes over 
time in remote zone T2 (<1 ms) were biologically insig-
nificant, and remote zone T1 (ms) was unchanged, indicat-
ing that the changes in ECV are much more likely because 
of progressive interstitial fibrosis than interstitial edema. In 
our previous work, remote zone native T1 was not associ-
ated with NT-proBNP,8 which is in contrast to the positive 
association between remote zone ECV and NT-proBNP. 
These results may be explained by the fact that ECV is a 
more specific biomarker of the extracellular space, whereas 
native T1 reflects both intracellular and extracellular com-
partments. Finally, for the first time, we have reported 
changes in remote zone ECV over time post MI and the 
associations with clinical characteristics and LV remodel-
ing. In agreement with previous observations,8 the absence 
of an association between remote zone ECV and the num-
ber of stenosed arteries suggest that ischemia is not a factor 
in remote zone remodeling. In linear regression analyses, λ 
had similar associations as ECV (data not shown), implying 
these variables are closely associated.
In this study, remote zone ECV exhibited a sex variation. 
This is in keeping with studies of remote zone ECV in patients 
with cardiovascular disease3,4 and healthy subjects.9,10 Sado et 
al10 also found height to be related to ECV, which agrees with 
our finding of the link between BMI and ECV. In contrast to 
findings by Ugander et al,3 we observed that remote zone ECV 
overlapped with the lower limits of infarct zone ECV. The 
possible explanations for this result include (1) large sample 
of an unselected real-world STEMI population in our study 
compared with a smaller sample (n=36) of patients studied by 
Ugander et al; (2) time between MI and CMR, which was not 
specified by Ugander et al and may have resulted in higher 
remote zone ECV in our study because of global edema and 
inflammatory cell influx, although the overlap persisted at 
6-month follow-up.
Our findings are evidence of associations between tissue 
characteristics in the myocardial remote zone and LV remod-
eling post STEMI.3,4,8 Although the effect size of the changes 
in ECV limits clinical use, the result is nonetheless important 
from the perspective of the pathophysiology and mechanisms 
of LV remodeling. On the contrary, we also observed that the 
size of infarction was a similar predictor of LV remodeling 
than remote zone ECV. Whether drugs that inhibit LV remod-
eling, for example, mineralocorticoid receptor antagonists, 
might have differential effects in patients according to their 
baseline ECV status (within the infarct and/or remote zones) 
Table 2. CMR Findings at Baseline (n=140) and at 6 Months (n=131) in Patients With STEMI Grouped by Tertiles of 
Remote Zone ECV (%) at Baseline
Characteristics*
STEMI Patient Tertiles, Remote Zone ECV at Baseline
P Value
All patients ≤24.2% >24.2 to ≤26.4% >26.4%
n=140 n=46 n=47 n=47
CMR findings 2 days post MI (n=140)
  LV ejection fraction, % 56±9 57±8 56±9 54±10 0.182
Edema and infarct characteristics
  Myocardial edema, % LV mass 31±11 29±12 30±11 35±9 0.033
  Myocardial salvage, % LV mass 19±8 18±7 18±8 22±9 0.025
Myocardial native T1 and T2 values
  T1 remote (all subjects), ms 961±24 953±20 963±26 967±23 0.010
  T2 remote, ms 49.9±2.1 48.9±1.9 50.1±2.3 50.7±1.9 <0.001
Myocardial ECV values
  ECV remote (all subjects), % 25.6±2.8 22.5±1.3 25.4±0.6 28.7±1.7 <0.001
  Men 25.2±1.8 22.6±1.3 25.4±0.6 28.8±1.8 <0.001
  Women 26.9±2.5 22.1±1.1 25.4±0.7 28.7±1.5 <0.001
Myocardial ECV values at 6 mo
  ECV remote at 6 mo  
(all subjects), %
25.7±2.8 24.3±2.4 25.3±2.3 27.6±2.5 <0.001
  Men 25.4±2.7 24.3±2.4 25.2±2.4 27.1±2.5 <0.001
  Women 26.9±2.7 24.2±1.0 25.4±2.3 28.3±2.4 0.002
Data are given as n (%) or mean±SD as appropriate. Myocardial edema was measured with T2-mapping. CMR indicates cardiac magnetic 
resonance; ECV, extracellular volume; LV, left ventricle; MI, myocardial infarction; STEMI, ST-elevation myocardial infarction; T1, longitudinal 
relaxation time; and T2, transverse relaxation time.
*P values were obtained from 1-way ANOVA, Kruskal–Wallis test, or Fisher test.
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merits further research. Wong et al11 observed that patients 
treated with renin-aldosterone-angiotensin system blockade 
had lower ECV.
Limitations
Postcontrast T1 maps were not acquired in all patients 
because of time constraints in our busy clinical service. 
CMR was performed at a single time point early post MI; 
therefore, we lack results on the temporal evolution of ECV 
post reperfusion. Angiotensin-converting enzyme inhibitors 
were prescribed in almost all patients with STEMI in our 
cohort (98%), and mineralocorticoid receptor antagonists 
were prescribed in the minority (4%); therefore, it was not 
possible to assess for associations between these therapies 
and ECV post MI. The relationship between remote zone 
ECV and health outcomes in STEMI survivors merits fur-
ther study in a larger population. We have undertaken the 
largest longitudinal study of remote zone ECV in patients 
after an acute STEMI. Nonetheless, the results do not pro-
vide evidence of causality.
Conclusions
In STEMI survivors, remote zone ECV is associated with sex, 
BMI, and a history of diabetes mellitus. Remote zone ECV 
at baseline and ΔECV are associated with the severity of MI 
including NT-proBNP. Only ΔECV was associated with LV 
remodeling, as revealed by CMR. ΔECV is implicated in the 
pathophysiology of LV remodeling post STEMI, but because 
the effect size is small, ΔECV has limited use as a clinical 
biomarker of remodeling.
Perspectives
Our findings provide further evidence of the pathophysiologi-
cal importance of remote zone tissue characteristics and LV 
remodeling in survivors of acute STEMI. Future research is 
warranted into the association between remote zone ECV and 
longer-term health outcomes. Remote zone ECV is implicated 
in the pathophysiology of LV remodeling.
Figure 2. Remote zone extracellular volume 
(ECV) at baseline versus change in remote 
zone ECV at follow-up.
Table 3. Multivariable Associates of the Change in Left 
Ventricular End-Diastolic Volume (ml) at 6 Months Post STEMI 
in 131 Patients
Multivariable Associations Coefficient (95% CI) P Value
ECV and clinical associates of remodeling
Change in remote  
zone ECV, %
1.43 (0.10 to 2.76) 0.036
Baseline remote zone ECV, % 0.86 (−0.41 to 2.13) 0.184
LV end-diastolic volume  
at baseline, ml
−0.28 (−0.38 to −0.17) <0.001
Male sex 15.40 (7.31 to 23.49) <0.001
Diabetes mellitus −10.34 (−19.71 to −0.97) 0.031
Previous angina −11.97 (−21.39 to −2.54) 0.013
Killip class IV 200.76 (165.40 to 236.12) <0.001
No ST-segment resolution 15.17 (6.69 to 23.64) 0.001
TIMI coronary flow grade 3 
pre PCI
−13.24 (−25.07 to −1.41) 0.029
TIMI coronary flow grade 2 
post PCI
−27.92 (−53.86 to −1.99) 0.035
The coefficient (95% CIs) indicates the magnitude and direction of the 
difference in change in LV end-diastolic volume (ml) for the patient characteristic 
(binary or continuous). When infarct size was included in the model, the change 
in remote zone ECV was no longer an associate of the change in LV end-diastolic 
volume.
CI indicates confidence interval; ECV, extracellular volume; LV, left ventricle; 
PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial 
infarction; and TIMI, thrombus in myocardial infarction.
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What Is New?
•	Extracellular volume (ECV) measured by cardiac magnetic resonance im-
aging has been measured in regions of interest repeatedly over time (2 
days and 6 months) in a reasonably large cohort of patients after acute 
ST-elevation myocardial infarction (MI).
•	ECV in the remote zone is associated with patient characteristics and 
the severity of MI.
•	The change in remote zone ECV is associated with left ventricular re-
modeling.
•	Remote zone ECV and the change in remote zone ECV are associated 
with NT-proBNP, a biochemical marker of MI severity.
What Is Relevant?
•	The change in remote zone ECV is implicated in the pathophysiology of 
LV remodeling post ST-elevation MI, but because the effect size is small, 
it has limited use as a clinical biomarker.
Summary
Remote zone ECV and the change in remote zone ECV over time are 
linked with clinical markers of MI severity as evidenced by reper-
fusion injury and myocardial edema. The change in remote zone 
ECV is linked with left ventricular remodeling during longer-term 
follow-up.
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Supplemental Methods 
Setting and study populations 
ST-elevation myocardial infarction patients 
Screening, enrolment, and data collection were prospectively performed by cardiologists in 
the cardiac catheterization laboratories of the Golden Jubilee National Hospital, Glasgow, 
United Kingdom. This hospital is a regional referral center for primary and rescue 
percutaneous coronary intervention (PCI). The hospital provides clinical services for a 
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population of 2.2 million. A screening log was recorded, including patients who did not 
participate in the cohort study. 
Healthy volunteers 
The purpose of including healthy volunteers was to collect normative reference data for 
myocardial extracellular volume (ECV) in individuals without prior cardiovascular disease or 
therapy and who were reasonably representative of the population of individuals from whom 
the ST-elevation myocardial infarction (STEMI) patients were drawn. Second, the reference 
ECV values were required to be measured on the same CMR scanner and with the same 
protocol that was used for the STEMI patients including during the same time-period. 
Healthy volunteers were invited to participate by placing adverts in public buildings (e.g. 
hospital, University) and through personal contacts of the researchers. Matching and selection 
of the healthy volunteers was done by the researchers in order to reflect the age and gender 
distribution of the STEMI patients. The healthy volunteers were resident in the same 
catchment area as the STEMI population. Age- and gender-matched healthy volunteers who 
had a normal electrocardiogram (ECG) and no prior history of cardiovascular disease or 
therapy underwent CMR during the same time period. The absence of late gadolinium 
enhancement (myocardial fibrosis or scar) was determined qualitatively by visual assessment, 
and the absence of late gadolinium enhancement was a requirement for inclusion of the 
volunteer in this analysis. 
The rationale for including healthy volunteers in this study is as follows. First, ECV values 
may vary between CMR scanners and so a local reference range for ECV is recommended in 
CMR guidelines [1, 2]. Second, ECV may vary spatially in the heart and therefore, since the 
focus of our study was to assess ECV in myocardium remote from the infarct zone, we aimed 
to collect ECV values in different segments of the heart in order to compare the remote zone 
ECV values from STEMI patients with reference spatially matched remote zone ECV values 
in age- and gender-matched healthy volunteers. Myocardial ECV values were regionally 
segmented in regions-of-interest and summarized according to the American Heart 
Association (AHA) model [3]. 
Coronary angiogram acquisition and analyses 
Coronary angiograms were acquired during usual care with cardiac catheter laboratory X-ray 
(Innova) and IT equipment (Centricity) made by GE Healthcare (Little Chalfont, UK).  
Percutaneous coronary intervention 
Consecutive admissions with acute STEMI referred for emergency percutaneous coronary 
intervention (PCI) were screened for the inclusion and exclusion criteria. During ambulance 
transfer to the hospital, the patients received 300 mg of aspirin, 600 mg of clopidogrel and 
5000 IU of unfractionated heparin [4, 5]. The initial primary PCI procedure was performed 
using radial artery access. A conventional approach to primary PCI was adopted in line with 
usual care in our hospital [4, 5]. Conventional bare metal and drug eluting stents were used in 
line with guideline recommendations and clinical judgment. The standard transcatheter 
approach for reperfusion involves minimal intervention with aspiration thrombectomy only or 
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minimal balloon angioplasty (e.g. a compliant balloon sized according to the reference vessel 
diameter and inflated at 4-6 atmospheres 1-2 times). During PCI, glycoprotein IIbIIIa 
inhibitor therapy was initiated with high dose tirofiban (25 g/kg/bolus) followed by an 
intravenous infusion of 0.15 g/kg/min for 12 hours, according to clinical judgment and 
indications for bail-out therapy [4, 5]. No reflow was treated according to contemporary 
standards of care with intra-coronary nitrate (i.e. 200 g) and adenosine (i.e. 30 – 60 g) [4, 
5], as clinically appropriate. In patients with multivessel coronary disease, multivessel PCI 
was not recommended, in line with clinical guidelines [4, 5]. The subsequent management of 
these patients was symptom-guided. 
Angiographic analysis 
The coronary anatomy and disease characteristics of study participants were described based 
on the clinical reports of the attending cardiologist.  
Outcome definitions 
Coronary blood flow can be described based on the visual assessment of coronary blood flow 
revealed by contrast injection into the coronary arteries [4, 5]. Thrombus in Myocardial 
Infarction (TIMI) Coronary Flow Grade 0 is no flow, 1 is minimal flow past obstruction, 2 is 
slow (but complete) filling and slow clearance, and 3 is normal flow and clearance. 
CMR acquisition 
CMR was performed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 1.5-Tesla 
scanner with a 12-element phased array cardiac surface coil.  
Myocardial native longitudinal relaxation time (T1) reflects tissue water content and 
cellularity [2]. T1-mapping was performed pre- and 15 minutes post-gadolinium contrast 
administration. T1 maps were acquired in 3 short-axial slices (basal, mid and apical), using a 
modified look-locker inversion-recovery (MOLLI) investigational prototype sequence 
(Work-in-Progress (WIP) method 448, Siemens Healthcare) [6-8] that incorporates an 
automatic registration algorithm based on a previously described approach [9]. The MOLLI 
T1 cardiac-gated acquisition involved three inversion-recovery prepared look locker 
experiments combined within one protocol (3 (3) 3 (3) 5) [7]. The CMR parameters were: 
bandwidth ~1090 Hz/pixel; flip angle 35°; echo time (TE) 1.1 ms; T1 of first experiment 100 
ms; TI increment 80 ms; matrix 192 x 124 pixels; spatial resolution 2.2 x 1.8 x 8.0 mm; slice 
thickness 8 mm; scan time 17 heartbeats . 
Myocardial T2 relaxation time directly reflects tissue water content and mobility [10,11]. T2-
mapping (WIP method 447, Siemens Healthcare) was acquired in contiguous short axis slices 
covering the whole ventricle, using an investigational prototype T2-prepared (T2P) TrueFisp 
sequence [10, 11]. The CMR parameters were: bandwidth ~947 Hz/pixel; flip angle 70°; T2 
preparations: 0 ms, 24 ms, and 55 ms respectively; matrix 160 x 105 pixels; spatial resolution 
2.6 x 2.1 x 8.0 mm; slice thickness 8 mm. 
Late gadolinium enhancement images covering the entire LV were acquired 10-15 minutes 
after intravenous injection of 0.15 mmol/kg of gadoterate meglumine (Gd2+-DOTA, Dotarem, 
Guebert S.A.) using segmented phase-sensitive inversion recovery (PSIR) turbo fast low-
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angle shot [12]. Microvascular obstruction (MVO) was defined as a dark zone on early 
delayed enhancement imaging 1, 3, 5 and 7 minutes post-contrast injection and within an area 
of late gadolinium enhancement at 10-15 minutes. Typical imaging parameters were: 
bandwidth ~130 Hz/pixel, flip angle 25, TE 3.36 ms, matrix 192 x 256 pixels, , echo spacing 
8.7ms and trigger pulse 2. The voxel size was 1.8 x 1.3 x 8 mm3. Inversion times were 
individually adjusted to optimize nulling of apparently normal myocardium (typical values, 
200 to 300 ms). 
Healthy volunteers underwent the same imaging protocol, with the exception that those <45 
years did not receive gadolinium. 
MR image analyses 
The images were analyzed on a Siemens work-station by observers with at least 3 years CMR 
experience (N.A., D.C., I.M, S.R.). All of the images were reviewed by experienced CMR 
cardiologists (C.B., N.T.). Left ventricular (LV) dimensions, volumes and ejection fraction 
were quantified using computer assisted planimetry (syngo MR®, Siemens Healthcare, 
Erlangen, Germany). All scan acquisitions were spatially co-registered.  
ECV measurement 
LV contours were delineated with computer-assisted planimetry on the best spatially matched 
raw T1 image and copied onto color-coded spatially co-registered maps. Care was taken to 
have adequate margins of separation from tissue interfaces, such as myocardium and blood, 
to prevent partial volume averaging [1, 2, 13]. Regions-of-interest (ROIs) were drawn in 1) 
remote myocardium, placed 180o from infarct zone; 2) infarct zone, including the entire area 
of injury; 3) LV blood pool. ROIs were copied between the pre- and post-contrast T1 maps 
with manual correction to maintain margins of separation from tissue interfaces. ECV was 
calculated as a ratio of corresponding T1 values measured pre- and post- contrast in each of 
the ROIs. No registration between T1 maps was therefore required for accurate calculation of 
ECV values. ECV was calculated using Eq. (1), where Lambda (λ)=ΔR1myocardium/ΔR1blood, 
R1=R1post-contrast-R1pre-contrast, R1=1/T1 [14, 15]. Hematocrit (HCT) was measured at the time 
of scanning.  
                             𝐸𝐶𝑉 = (1 − 𝐻𝐶𝑇)  ×  λ           (1) 
ECV analysis in the healthy volunteer cohort was calculated for 6 equal segments (anterior, 
anterolateral, inferolateral, inferior, inferoseptal, anteroseptal) of the mid-ventricular T1 maps 
according to the 17-segment model of the American Heart Association (AHA) [3]. Per-
segment values were averaged to give a global ECV for each case. To expand the healthy 
volunteer cohort, synthetic HCT was calculated using the equation HCT = 0.88-(T1blood/3240) 
[16]. 
Infarct definition and size 
The presence of acute infarction was established based on abnormalities in cine wall motion, 
rest first-pass myocardial perfusion, and delayed-enhancement imaging. In addition, 
supporting changes on the ECG and coronary angiogram were also required. Acute infarction 
was considered present only if late gadolinium enhancement was confirmed on both the axial 
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and long axis acquisitions. The territory of infarction was delineated using a signal intensity 
threshold of >5 standard deviations (SD) above a remote reference region and expressed as a 
percentage of total LV mass [13]. Infarct regions with evidence of MVO were included 
within the infarct area and the area of MVO was assessed separately and also expressed as a 
percentage of total LV mass. 
Microvascular obstruction 
MVO was defined as a dark zone on early gadolinium enhancement imaging 1, 3, 5 and 7 
minutes post-contrast injection that remained present within an area of late gadolinium 
enhancement at 10-15 minutes. The late time-point was used to delineate MVO [1]. 
Identification of MVO was performed independently by I.M. and N.A. MVO area was 
assessed separately and expressed as a percentage of LV mass. 
Myocardial edema 
The extent of myocardial edema was defined as LV myocardium with pixel values (T1/T2) 
>2 SD from remote myocardium [17-18]. In order to assess myocardial edema the epicardial 
and endocardial contours on the last corresponding T2-weighted raw image with an echo time 
of 55 ms were planimetered [19]. Contours were then copied to the map and corrected when 
necessary by consulting the SSFP cine images.  
Myocardial salvage 
Myocardial salvage was calculated by subtraction of percent infarct size from percent 
myocardial edema (a retrospective estimate of the initial ischemic area-at-risk) [20-22]. The 
myocardial salvage index was calculated by dividing the myocardial salvage area by the 
initial extent of edema (% LV mass). 
Adverse remodeling 
Adverse remodeling was defined as an increase in LV end-diastolic volume ≥ 20% at 6 
months from baseline [23]. 
Reference ranges 
Reference ranges used in the laboratory were 105 – 215 g for LV mass in men, 70 – 170 g for 
LV mass in women, 77 – 195 ml for LV end-diastolic volume in men, 52 – 141 ml for LV 
end-diastolic volume in women, 19 – 72 ml for LV end-systolic volume in men and 13 – 51 
ml for LV end-systolic volume in women.  
Electrocardiogram 
A 12 lead ECG was obtained before coronary reperfusion and 60 minutes afterwards with 
Mac-Lab technology (GE Healthcare) in the catheter laboratory and a MAC 5500 HD 
recorder (GE Healthcare) in the Coronary Care Unit. The ECGs were acquired by trained 
cardiology staff. The ECGs were de-identified and transferred to the local ECG management 
system. The ECGs were then analyzed by the University of Glasgow ECG Core Laboratory 
which is certified to ISO 9001: 2008 standards as a UKAS Accredited Organization.  
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The extent of ST-segment resolution on the ECG assessed 60 minutes after reperfusion 
compared to the baseline ECG before reperfusion [4] was expressed as complete (70%), 
incomplete (30% to < 70%) or none (30%). 
Biochemical assessment of infarct size 
Troponin T was measured (Elecsys Troponin T, Roche) as a biochemical measure of infarct 
size. The high sensitive assay reaches a level of detection of 5 pg/ml and achieves less than 
10% variation at 14 pg/ml corresponding to the 99th percentile of a reference population. A 
blood sample was routinely obtained 12 – 24 hours after hospital admission, and again 
between 0700 – 0900 hours during the first two days of the index hospitalization. 
Biochemical measurement of LV remodeling 
Serial systemic blood sample were obtained immediately after reperfusion in the cardiac 
catheterization laboratory, and subsequently between 0600 - 0700 hrs each day during the 
initial in-patient stay in the Coronary Care Unit.  
NT-proBNP, a biochemical measure of LV wall stress, was measured in a research laboratory 
using an electrochemiluminescence method (e411, Roche)  and the manufacturers calibrators 
and quality control material. The limit of detection is 5 pg/ml. Long-term coefficient of 
variations of low and high controls are typically <5%, and were all within the manufacturers 
range. 
Research Management 
The study was conducted in line with Guidelines for Good Clinical Practice (GCP) in Clinical 
Trials [24].  
Research management included a Management Group, and an independent Clinical Trials 
Unit. Day to day study activity was coordinated by the Management Group who was 
responsible to the Sponsor which was responsible for overall governance and that the trial 
was conducted according to GCP standards.  
Supplemental Results 
The flow diagram for the study is shown in Supplemental Fig. S1. 
Remote zone ECV inter-observer reliability 
Remote ECV in a subgroup of 20 randomly chosen patients was independently measured by 
two observers. The ICC for reliability of remote zone ECV was 0.92 (95% confidence 
interval (CI): 0.79, 0.97); p<0.001). The mean absolute difference between measures was 
0.48%, and the root-mean-square error was 1.01. Bland-Altman plots showed no evidence of 
bias (Supplemental Fig. S2). The coefficient of variation for values of remote zone ECV at 
baseline in STEMI patients (n=140) was 13.36. 
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Remote zone ECV in healthy volunteers 
Twenty-eight healthy volunteers (mean±SD 60±11 years, 16 (57%) male) with no history of 
cardiovascular disease or treatment had CMR scans including post-contrast T1-mapping with 
MOLLI. Volunteers were scanned using the same 1.5 Tesla MRI scanner (Siemens 
AVANTO) as the STEMI patients. Twenty patients had available HCT measures on the day 
of scanning. For these patients, synthetic ECV and conventional ECV were highly correlated 
(R2=0.82, p<0.001). The correlation was similar for synthetic and conventional remote ECV 
in STEMI patients (R2=0.68, p<0.001). SD of differences for healthy volunteers was 1.3%. 
The Bland-Altman plot showed no evidence of bias (Supplemental Fig. S3). Regression 
coefficients between synthetic and conventional ECV measurements were similar. We 
proceeded to calculate synthetic HCT and ECV for the remaining healthy volunteers, giving a 
total of n=28 healthy volunteers. 
At the mid ventricular level, remote zone synthetic ECV was similar in STEMI patients and 
healthy volunteers for a sex-matched grouped (n=21, age 58±12 years, 76% male) 
(24.2±2.7% vs. 24.1±2.6%; p=0.959). In all healthy volunteers (n=28), remote zone ECV was 
higher in females than in males (25.6±2.4% vs. 23.0±1.7%; p=0.002). Overall, remote zone 
ECV was negatively associated with age (-0.09 (-0.16, -0.01); p=0.027), however the 
association was sex-dependent (women: -0.16 (-0.27, -0.04); p=0.015; men: -0.03 (-0.11, 
0.06); p=0.498). There was a trend to interaction between age and sex when assessed using 
linear regression (p=0.052). ECV was higher in septal segments in females (anteroseptal: 
25.8±3.0% vs. 22.9±1.9%; p=0.004; inferoseptal: 25.9±2.9% vs. 22.6±1.8%; p=0.001), 
whereas no differences were observed for other segments (anterior: 24.1±3.4% vs. 
22.0±1.9%; p=0.077; anterolateral: 23.9±3.7% vs. 23.0±1.8%; p=0.457; inferolateral: 
25.7±3.6% vs. 24.5±2.2%; p=0.309; inferior: 25.3±3.8% vs. 23.8±2.6%; p=0.283). 
The coefficients of variation for remote zone ECV in the mid-ventricular level with regions-
of-interest within myocardial regions were: anterior CoV = 12.54; anterolateral CoV = 12.09; 
anteroseptal CoV = 11.53; inferior CoV = 13.26; inferolateral CoV = 11.55; inferoseptal CoV 
= 11.83. 
Univariable associates with the change in LV end-diastolic volume at 6 months in all 
patients 
Characteristics also included in the model include age (p=0.437), BMI (p=0.437), cigarette 
smoking (p=0.394), history of hypertension (p=0.846), hypercholesterolemia (0.958), 
previous PCI (p=0.150), previous MI (p=0.057), heart rate (p=0.183), systolic blood pressure 
at initial angiography (p=0.848), symptoms to reperfusion time (p=0.210), sustained 
ventricular arrhythmia (p=0.956), TIMI coronary flow grade 2 pre-PCI vs. TIMI coronary 
flow grade 0/1 pre-PCI (reference category) (p=0.465), rescue PCI vs. primary PCI (reference 
category) (p=0.525), incomplete ST-segment resolution vs. complete ST-segment resolution 
(reference category) (p=0.474), TIMI coronary flow grade 3 post-PCI vs. TIMI coronary flow 
grade 0/1 post-PCI (reference category) (p=0.191), Killip class II vs. Killip class I (reference 
category) (p=0.239), Killip class III vs. Killip class I (reference category) (p=0.110). 
The multivariable predictors of the change in LV end-diastolic in all patients are described in 
Table 3 of the main paper. 
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Remote zone ECV and health outcomes in the longer term 
Health outcome data was available in 140 (100%) patients. The median duration of follow-up 
was 724 days (minimum-maximum post-discharge censor duration 598- 923 days). Twelve 
(9%) patients experienced a major adverse cardiac event (MACE), including 6 recurrent MI 
hospitalizations and 6 heart failure episodes (hospitalization with Killip Class 3 or 4 heart 
failure or defibrillator implantation). Seven (5%) patients experienced a MACE post-
discharge. Remote zone ECV was not associated with MACE (n=12). All-cause death or 
heart failure hospitalization occurred in 7 (5%) patients, including 1 death and 6 heart failure 
episodes. Three (2%) patients experienced an event post-discharge. Remote zone ECV was 
not associated with all cause death and heart failure hospitalization (n=7) (hazard ratio (95% 
confidence interval) 1.08 (0.73, 1.59)).   
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Supplemental Tables 
Supplemental Table S1. CMR findings at baseline (n=140) and at 6 months (n=131) in STEMI patients grouped by tertiles of remote zone ECV 
(%) at baseline. 
Characteristics*  STEMI patient tertiles,  
remote zone ECV at baseline 
P-value 
 All patients ≤24.2% >24.2 to ≤26.4% >26.4%  
 n=140 n=46 n=47 n=47  
CMR findings 2 days post-MI (n=140)      
LV ejection fraction, % 56±9 57±8 56±9 54±10 0.182 
LV end-diastolic volume, ml      
Men 162±34 158±41 162±31 167±23 0.532 
Women 125±24 121±22 133±26 120±23 0.389 
LV end-systolic volume, ml      
Men 75±26 70±30 76±26 81±21 0.213 
Women 53±16 56±14 53±16 53±18 0.955 
LV mass, g      
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Men 146±37 147±42 146±31 144±36 0.753 
Women 101±22 107±31 105±23 97±20 0.699 
Edema and infarct characteristics      
Myocardial edema, % LV mass 31±11 29±12 30±11 35±9 0.033 
Infarct size, % LV mass 17±12 17±12 16±12 18±12 0.606 
Myocardial salvage, % LV mass 19±8 18±7 18±8 22±9 0.025 
Myocardial salvage index, % LV mass 63±23 61±20 63±22 65±25 0.585 
Late microvascular obstruction present, n (%) 70 (50) 26 (57) 20 (43) 24 (51) 0.412 
Late microvascular obstruction, % LV mass 2.3±4.5 1.9±4.5 2.4±4.7 2.5±4.3 0.804 
Myocardial native T1 and T2 values      
T1 remote (all subjects, ms) 961±24 953±20 963±26 967±23 0.010 
Men 959±24 952±20 963±27 966±25 0.025 
Women 967±21 969±17 965±25 969±20 0.866 
T1 infarct, ms 1100±51 1103±53 1103±51 1096±48 0.737 
T1 hypointense core present, n (%) 74 (53) 24 (52) 23 (49) 27 (57) 0.704 
T1 hypointense infarct core, ms 1004±63 1001±61 1007±68 1005±64 0.939 
T2 remote, ms 49.9±2.1 48.9±1.9 50.1±2.3 50.7±1.9 <0.001 
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Myocardial ECV values      
ECV remote (all subjects), % 25.6±2.8 22.5±1.3 25.4±0.6 28.7±1.7 <0.001 
Men  25.2±1.8 22.6±1.3 25.4±0.6 28.8±1.8 <0.001 
Women 26.9±2.5 22.1±1.1 25.4±0.7 28.7±1.5 <0.001 
ECV infarct, % 51.4±8.9 50.4±10.1 51.0±7.5 52.9±9.0 0.363 
ECV hypointense infarct core, % 43.2±12.1 40.4±9.7 44.2±13.5 44.9±12.9 0.390 
ECV infarct zone out-with the infarct core, % 55.8±11.6 53.6±11.5 55.7±11.3 58.2±11.9 0.155 
CMR findings 6 months post-MI (n=131)      
LV ejection fraction at 6 months, % 63±9 63±9 63±9 63±10 0.988 
LV end-diastolic volume at 6 months, ml      
Men 165±43 164±56 164±36 168±30 0.456 
Women 123±18 109±14 130±16 121±18 0.157 
LV end-systolic volume at 6 months, ml      
Men 65±36 64±46 64±30 67±25 0.376 
Women 43±17 40±21 46±14 42±18 0.585 
Myocardial ECV values at 6 months      
ECV remote at 6 months (all subjects), % 25.7±2.8 24.3±2.4 25.3±2.3 27.6±2.5 <0.001 
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Men 25.4±2.7 24.3±2.4 25.2±2.4 27.1±2.5 <0.001 
Women 26.9±2.7 24.2±1.0 25.4±2.3 28.3±2.4 0.002 
ECV infarct at 6 months, % 51.4±10.3 51.9±10.1 49.6±10.2 52.6±10.7 0.368 
Footnote: Abbreviations: ECV = extracellular volume, LV = left ventricle, T1 = longitudinal relaxation time, T2 = transverse relaxation time. 
Myocardial edema was measured with T2-mapping.  
Data are given as n (%) or mean±SD, as appropriate. *P-values were obtained from one-way ANOVA, Kruskal-Wallis test, or Fischer’s test. 6 
month ECV values were available in 131 patients. 
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Supplemental Table S2. Multivariable association of patient characteristics at initial 
presentation with baseline remote zone ECV assessed by CMR 2 days after reperfusion 
(n=140).   
Multivariable associations coefficient (95% CI) P-value 
Patient characteristics, angiographic data and LV ejection fraction 
Male sex -1.85 (-2.91, -0.79) 0.001 
BMI, kg/m2 -0.12 (-0.22, -0.02) 0.018 
Diabetes mellitus 1.82 (0.43, 3.20) 0.010 
LV ejection fraction, % -0.08 (-0.13, -0.03) 0.002 
Patient characteristics, angiographic data and myocardial edema 
Male sex -1.61 (-2.63, -0.60) 0.002 
BMI, kg/m2 -0.14 (-0.24, -0.04) 0.006 
Diabetes mellitus 1.85 (0.49, 3.21) 0.008 
History of MI 1.90 (0.19, 3.62) 0.030 
Myocardial edema, % LV mass 0.09 (0.05, 0.14) <0.001 
Patient characteristics, angiographic data and remote zone T2 
Male sex -1.41 (-2.47, -0.35) 0.010 
Diabetes mellitus 1.53 (0.14, 2.93) 0.032 
T2 remote, ms 0.35 (0.14, 0.57) 0.001 
Patient characteristics, angiographic data and remote zone T1 
Male sex -1.22 (-2.28, -0.16) 0.024 
BMI, kg/m2 -0.13 (-0.23, -0.03) 0.010 
Diabetes mellitus 1.70 (0.32, 3.07) 0.016 
T1 remote, ms 0.04 (0.02, 0.06) <0.001 
Footnote: Abbreviations: BMI = body mass index, CI = confidence interval, LV = left 
ventricle, MI = myocardial infarction, T1 = longitudinal relaxation time, T2 = transverse 
relaxation time. 
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The coefficient (95% confidence intervals) indicates the magnitude and direction of the 
difference in remote zone ECV(%) for the patient characteristic (binary or continuous).  
The clinical characteristics that were univariably associated with remote zone ECV at 
baseline that were also included in the model were age (p=0.406), current smoker (p=0.483), 
hypertension (p=0.114), hypercholesterolemia (p=0.348), previous angina (p=0.335), 
previous MI (p=0.217), previous PCI (p=0.884), symptom onset to reperfusion time 
(p=0.637), systolic blood pressure at initial angiography (p=0.508),  heart rate (p=0.589), 
TIMI coronary flow grade 2 at initial angiography vs. TIMI coronary flow grade 0/1 at initial 
angiography (reference category) (p=0.530), TIMI coronary flow grade 3 at initial 
angiography vs. TIMI coronary flow grade 0/1 at initial angiography (reference category) 
(p=0.342), TIMI coronary flow grade 2 post-PCI vs. TIMI coronary flow grade 0/1 post-PCI 
(reference category) (p=0.810), TIMI coronary flow grade 3 post-PCI vs. TIMI coronary flow 
grade 0/1 post-PCI (reference category) (p=0.777), no ST-segment resolution vs. complete 
ST-segment resolution (reference category) (p=0.528), incomplete ST-segment resolution vs. 
complete ST-segment resolution (reference category) (p=0.562), Killip class III vs. Killip 
class I (reference category) (p=0.738), Killip class IV vs. Killip class I (reference category) 
(p=0.529).  
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Supplemental Table S3. Multivariable regression analysis of clinical characteristics and  
ΔECV (n=131).  
Multivariable associations coefficient (95% CI) P-value 
Patient characteristics and angiographic data 
Baseline remote zone ECV, % -0.48 (-0.62, -0.34) <0.001 
BMI, kg/m2 -0.14 (-0.23, -0.04) 0.005 
No ST-segment resolution 1.20 (0.09, 2.31) 0.034 
Patient characteristics, angiographic data and myocardial edema 
Baseline remote zone ECV, % -0.62 (-0.76, -0.48) <0.001 
Age, years 0.03 (0.00, 0.07) 0.044 
BMI, kg/m2 -0.13 (-0.22, -0.04) 0.004 
Myocardial edema, % of LV mass 0.08 (0.04, 0.11) <0.001 
Footnote: Abbreviations: BMI = body mass index, CI = confidence interval, ECV = 
extracellular volume, LV = left ventricle.  
The coefficient (95% confidence intervals) indicates the magnitude and direction of the 
difference in ΔECV(%) for the patient characteristic (binary or continuous). Lambda = 
ΔR1myocardium/ΔR1blood. 
Characteristics also included in the model were age (p=0.275), gender (p=0.482), diabetes 
mellitus (p=0.184), current smoker (p=0.216), hypertension (p=0.767), hypercholesterolemia 
(p=0.899), previous angina (p=0.646), previous MI (p=0.754), previous PCI (p=0.310), 
symptom onset to reperfusion time (p=0.260), systolic blood pressure at initial angiography 
(p=0.626),  heart rate (p=0.296), rescue PCI vs. primary PCI (reference category) (p=0.529), 
TIMI coronary flow grade 2 at initial angiography vs. TIMI coronary flow grade 0/1 at initial 
angiography (reference category) (p=0.855), TIMI coronary flow grade 3 at initial 
angiography vs. TIMI coronary flow grade 0/1 at initial angiography (reference category) 
(p=0.217), sustained ventricular arrhythmia (p=0.240), TIMI coronary flow grade 2 post-PCI 
vs. TIMI coronary flow grade 0/1 post-PCI (reference category) (p=0.145), TIMI coronary 
flow grade 3 post-PCI vs. TIMI coronary flow grade 0/1 post-PCI (reference category) 
(p=0.344), incomplete ST-segment resolution vs. complete ST-segment resolution (reference 
category) (p=0.355), Killip class II vs. Killip class ( (reference category) (p=0.520), Killip 
class III vs. Killip class I (reference category) (p=0.380), Killip class IV vs. Killip class I 
(reference category) (p=0.789).   
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Supplemental Figures 




















CONSORT flow diagram.  
Acute STEMI patients assessed 
for eligibility  
(n = 178) 
No ECV at 6 months follow-up (n = 9) 
 No post-contrast T1 map (n = 1) 
 Refused (n = 8) 
Analysis 
Follow-up 
CMR (n = 167) 
Enrolment with informed 
consent 
CMR with post-contrast 
T1 map (n = 140) 
CMR 6 months post-MI 
(n = 132) 
Post-contrast T1 maps 6 months post-MI 
(n = 131) 
CMR without post-contrast T1 map (n = 27) 
 Lack of scanner time  
No CMR (n = 11) 
 Claustrophobia (n = 8) 
 Death (n = 1) 
 Contraindication to CMR (n = 2) 
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Supplemental Figure S2.  
  
Bland-Altman plot for inter-observer variability in remote zone ECV measurement.   
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Supplemental Figure S3.  
 
Bland-Altman plot for agreement between conventionally measured ECV and synthetic ECV 
in 20 healthy volunteers. 
